NEW YORK, April  30, 2026  (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (&#34;Aldeyra&#34; or the &#34;Company&#34;) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff

ALDX

REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026

Aldeyra Faces Class Action Over Drug Trial Disclosures; Share Price Decline

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, April  30, 2026  (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (&amp;#34;Aldeyra&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Aldeyra Therapeutics is facing a class action lawsuit for allegedly failing to disclose significant inconsistencies in clinical trial results for reproxalap. Following a 71% drop in share price after receiving an unfavorable FDA response, investor confidence may remain low as the lawsuit proceeds.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Aldeyra faces a class action lawsuit over clinical trial disclosures.</li><li>The lawsuit alleges inconsistencies in reproxalap clinical trial results.</li><li>Shares fell 71% following an FDA Complete Response Letter.</li><li>Deadline for lead plaintiff application in the lawsuit is May 29, 2026.</li><li>Investors can acquire information regarding their rights through legal counsel.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Aldeyra Therapeutics, Inc. (ALDX)</strong>: Facing significant legal challenges impacting market perception.</li><li><strong>Kirby McInerney LLP (N/A)</strong>: Legal firm reminding investors of class action rights.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This falls under &#039;Legal&#039; due to ongoing litigation affecting stock performance. Legal challenges can significantly impact investor sentiment and company valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>FDA&#039;s negative feedback on reproxalap contributed to a significant share price drop.</li><li>Class action announcement may discourage investment and lower stock demand.</li><li>Potential settlement payouts could impact Aldeyra&#039;s cash flow and valuation.</li><li>Ongoing investor litigation could keep shares volatile in the near term.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Aldeyra&#039;s share price dropped from $4.23 to $1.24 on March 17, 2026.</li><li>The class action period spans from November 3, 2023 to March 16, 2026.</li><li>May 29, 2026 is the deadline to apply as lead plaintiff.</li><li>FDA Complete Response Letter cites inadequate evidence for drug effectiveness.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider shorting ALDX given ongoing litigation and declining confidence.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">NEW YORK, April  30, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=D6mCjLZ6ZQI2y2-cLUVeK-5s3jh7EFX06tBDN1WLNSWRByES2CPDV0N45B8wKE90nzfiyTkjEPQPTM5Mqg6ePaxvpLBdMAcLgBWtKU-5__Q=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> reminds Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ALDX">ALDX</a>) investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.</p>  <p align="justify">If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more, please contact <a href="https://www.globenewswire.com/Tracker?data=bPCUaaXHBG08Fh385mWx4aMgk05_kn8LXxd1_bPXxyQ6H-ubIRcBDq3ZFwlxzMwKmmYUundWdltN9AsLSd-5h--Go92D8GN3AmBmuiR8_tTEUxGjWhI5--K7ZK1wMp7u" rel="nofollow" target="_blank">Lauren Molinaro</a> of Kirby McInerney LLP by email at <a href="https://www.globenewswire.com/Tracker?data=iw7Cu_-RFNQjRf0i8UaXJ2YahiOWJkJJK1yZxY0RAnHlpkRPbkO16nxPB9Ja-I5Jmf2G1n-F78dsn5vlnGI8HNvlZ6djG92TPW4KQMrGAYSEqIMNu5cg3nNG91vUas_P" rel="nofollow" target="_blank">investigations@kmllp.com</a>, or fill out the form below, to discuss your rights or interests.</p>  <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=uj5PGnJGgf0isv6NvnCA18NuthsOdgrXc32Wv5opSW4aOlZTh2oam32JHmmnKxQHIFq4S_Ysm4PUbrX8vecEYF3UsyVxVFumE6mvSMRjHVFzPiZsNrPYmrwP7JzDNhjAZbDVG3Wqt7am05Z1Mc6MXuEkEs_QhVPQRMaS7eLraH9z-E_sp5xVaXdMXK3EshrC" rel="nofollow" target="_blank">CONTACT THE FIRM IF YOU SUFFERED A LOSS</a>]</p>  <p align="justify"><strong>What Is The Lawsuit About?</strong></p>  <p align="justify">The lawsuit has been filed on behalf of investors who purchased securities during the period of November 3, 2023 through March 16, 2026, inclusive ("the Class Period"). The lawsuit alleges that Aldeyra failed to disclose that (1) the results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; and (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful.</p>  <p align="justify">On March 17, 2026, the Company filed with the SEC a current report on Form 8-K, announcing receipt of a Complete Response Letter from the FDA, stating that there is "a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling" and that "the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease." The Complete Response Letter also stated that the "inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings" and that "the totality of evidence from the completed clinical trials does not support the effectiveness of the product." On this news, the price of Aldeyra shares declined by $2.99 per share, or approximately 71%, from $4.23 per share on March 16, 2026 to close at $1.24 on March 17, 2026.</p>  <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=2MUN6vXUa_r9MHGYnxcqAKa3YcfYc56-4xq2_OTWh91W21rhwfjRbzGXr8naQsomWRU0POy5SYK-2EN77HlDt2af7N4H68bKU5_mMgqoPjQ900WwjyGn0d3IqNglFw71__OdQg8lbc2A1LTpSxb4OqLtJvNbBMW7i7iwGgyZ9VySkm7_V960VViUPxrpfH7C" rel="nofollow" target="_blank">CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION</a>]</p>  <p align="justify"><strong>What Should I Do?</strong></p>  <p align="justify">If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more about this investigation, please contact <a href="https://www.globenewswire.com/Tracker?data=bPCUaaXHBG08Fh385mWx4aNo0tSzCsdi4zOXhGCIwb4JGSrWUOiEXpwax__ebQo08Dzbwlm-2rWN8GKx960z7avQVVA8OFX1Gk61FJ2iurZc0anozL0gPy9hbhuSwpXZ" rel="nofollow" target="_blank">Lauren Molinaro</a> of <a href="https://www.globenewswire.com/Tracker?data=D6mCjLZ6ZQI2y2-cLUVeK2SORTzFiI5JENAOR-PdGH7N3J4-ND4e_d6Lq6oJoSF0Ikq0chQ_GS333ACL1e7lBeGqWoh4GAybP82D9yRxHuA=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> by email at <a href="https://www.globenewswire.com/Tracker?data=iw7Cu_-RFNQjRf0i8UaXJ2YahiOWJkJJK1yZxY0RAnGGqhIl6zEB6a7QU7ZNgtCBVokEzUn7y2UJuGoozWWMUSdg6iqXWV0K8ScZT6KtrbMLP7dvBTdvHXg_Cx5FHxap" rel="nofollow" target="_blank">investigations@kmllp.com</a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.</p>  <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=CB5YYiFac3OpjZvpoGO009vNgxBNpzZIgBWdQ5hxILw-_eHUrr-_w0c_-VI7f27R-HI14wCKL_7ZKY4NEIqJGTmNxqWrx-rHHmrBTwpyuSExGVbiiiLHR6yB4lAuQwiIKaW3CbFE2BRGYyVvJwPykQ==" rel="nofollow" target="_blank">WHAT IS A SECURITIES CLASS ACTION?</a>]</p>  <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=D6mCjLZ6ZQI2y2-cLUVeK-5s3jh7EFX06tBDN1WLNSXnaDIHRcpZ1fz_QD3ecU7vdzQL7aYMVinTBAWjRlld6kdbs_XGwRc_XJ0GwGjDEfY=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's <a href="https://www.globenewswire.com/Tracker?data=kmJgJY5csqXF0jB8xSLWz1TS1a_zb0Nr0KVXGAyY3YnnZ03TrxbIIK2wOQuqH0kMEoZ3_xgAUH2iRALXC__2Dw==" rel="nofollow" target="_blank">website</a>.</p>  <p align="justify">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p>  <p align="justify">Contacts<br></br>Kirby McInerney LLP        <br></br>Lauren Molinaro, Esq.<br></br>212-699-1171<br></br><a href="https://www.globenewswire.com/Tracker?data=PQa-UvAO7UmaEzngRHi5O2v77kSSp1zb0UvlZI0atuEpdF0VqYpBssr9kGCnVIVGUL85kiLERki7QeK07alNqAKawTz7aSdaONR_KSgyTXo=" rel="nofollow" target="_blank">https://www.kmllp.com</a><br></br><a href="https://www.globenewswire.com/Tracker?data=PQa-UvAO7UmaEzngRHi5Ox1dbFSnb4-kOl_beMZpm0un42l9NaSmTxVlDXbtWFek-v0RCo1lx0moOe5YFRu7Tt9lHObM4vTq8cztJeK20sz-xdbIG4teXXmfTXerguQ2v5HwPSau7QI8HSKAd-h6Nw==" rel="nofollow" target="_blank">https://securitiesleadplaintiff.com/</a><br></br><a href="https://www.globenewswire.com/Tracker?data=iw7Cu_-RFNQjRf0i8UaXJ2YahiOWJkJJK1yZxY0RAnEqq3aXH6RgZxvIVOI0TOy4Bc2NFa7j1xQ528g-CZ5r0dr-YHAjC2eIT64-LKe-6VQj5pYrWqTVIAV6XrNB9qKJ" rel="nofollow" target="_blank">investigations@kmllp.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OWU5YTE1MmUtN2I1Yi00NTljLWI3ZTQtODQzNmQ1MzFkOTY2LTEwMzE5OTctMjAyNi0wNC0zMC1lbg==/tiny/Kirby-McInerney-LLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/192da1d1-643f-4eee-b850-dde5b9f2b00f"><img src="https://ml.globenewswire.com/media/192da1d1-643f-4eee-b850-dde5b9f2b00f/small/linkedin-logo-300x300-png.png" border="0" width="147" height="147" alt="Primary Logo"></img></a></p>

Aldeyra Therapeutics is facing a class action lawsuit for allegedly failing to disclose significant inconsistencies in clinical trial results for reproxalap. Following a 71% drop in share price after receiving an unfavorable FDA response, investor confidence may remain low as the lawsuit proceeds.

REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News